KBC Group NV increased its holdings in MetLife, Inc. by 1.3% in the fourth quarter, bringing its total ownership to 1,420,569 shares valued at $112.14 million. MetLife recently reported strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating with an average target price of $93.38. The company faces both positive news, such as shareholder protection against a mini-tender offer and non-insurance revenue from MetLife Stadium, and potential risks like negative publicity surrounding World Cup transit fares and a recent price target cut by Bank of America.

KBC Group NV increased its stake in Merck & Co., Inc. by 9.2% in the fourth quarter, acquiring an additional 107,602 shares to hold a total of 1,278,131 shares valued at $134.5 million. This comes as Merck reported strong Q4 earnings, beating analyst estimates, and set positive FY2026 guidance. Despite some insider selling, analysts maintain a "Moderate Buy" rating for the pharmaceutical giant with an average price target of $128.47.

KBC Group NV significantly increased its stake in Amgen Inc. by 17.9%, now holding 572,145 shares worth approximately $187.27 million. This comes as Amgen exceeded earnings expectations for the last quarter, reporting $5.29 EPS against an expected $4.76 and setting positive FY2026 guidance. Analysts currently maintain a "Hold" rating for Amgen, with an average price target of $356.24.

KBC Group NV significantly increased its stake in Monster Beverage Corporation (MNST), purchasing an additional 242,174 shares in Q4, bringing its total holdings to 1,212,776 shares valued at approximately $92.98 million. Monster Beverage outperformed quarterly expectations with $0.51 EPS and $2.10 billion in revenue, showing strong year-over-year growth and profitability. Institutional investors hold 72.36% of the stock, and analysts maintain a "Moderate Buy" consensus with a target price of $83.38.

Lbp Am Sa significantly increased its holdings in American Tower Corporation (NYSE:AMT) by 47.7% in the fourth quarter, bringing its total ownership to 104,398 shares valued at $18.33 million. Other institutional investors also adjusted their positions, and insider activity included a large sale by the COO and a purchase by a director. The article also covers recent analyst rating changes and financial performance details for American Tower.

KBC Group NV reduced its stake in Arista Networks by 18.2% in the fourth quarter, selling 257,170 shares, though it still holds over 1.1 million shares worth approximately $151.6 million. This sale comes amidst other significant insider selling, including by CEO Jayshree Ullal, which could impact near-term investor sentiment. Despite insider sales, Arista Networks reported strong earnings, benefiting from AI infrastructure demand, and analysts maintain a bullish "Buy" consensus with price targets reaching up to $200.

KBC Group NV reduced its stake in Bank of America (NYSE:BAC) by 0.9% during the fourth quarter, selling 81,789 shares, but still holds over 9.1 million shares valued at approximately $502.8 million. Other institutional investors also adjusted their positions in BAC. The article also provides recent analyst ratings, financial performance, dividend information, and details on insider activity for Bank of America.

KBC Group NV increased its stake in Boston Scientific Corporation (NYSE:BSX) by 2.9% during the fourth quarter, now owning 3,044,385 shares valued at $290.28 million. Other institutional investors also adjusted their holdings, and 89.07% of the stock is currently owned by institutional investors. Recent news for Boston Scientific includes continued analyst support, positive earnings expectations, an update on the competitive landscape, and rising legal risk due to recent class-action lawsuit filings.

KBC Group NV increased its stake in Citigroup Inc. (NYSE:C) by 3.4% in the fourth quarter, now owning 3,839,880 shares valued at $448.075 million. The article also highlights recent positive analyst ratings and forecasts for Citigroup, along with a strong Q1 earnings report that beat expectations. However, it also notes negative sentiments regarding the company's private-credit exposure and increased regulatory scrutiny in that market.

KBC Group NV increased its stake in Pfizer Inc. by 8.3% during the fourth quarter, purchasing 706,426 additional shares to bring its total holding to 9,193,713 shares, valued at approximately $228.9 million. This makes KBC Group NV own about 0.16% of Pfizer, with institutional investors collectively owning 68.36% of the company. Despite Pfizer beating Q4 earnings estimates with an EPS of $0.66 and revenue of $17.56 billion, analysts maintain a consensus "Hold" rating with a target price of $28.24.